Abstract
Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 242-245 |
| Number of pages | 4 |
| Journal | Journal of Clinical Neuroscience |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 2005 |
Keywords
- Brain metastases
- Irinotecan
- Whole brain radiation
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Neurology
Fingerprint Dive into the research topics of 'Complete response of brain metastases to irinotecan-based chemotherapy'. Together they form a unique fingerprint.
Cite this
Chou, R., Chen, A., & Lau, D. H. (2005). Complete response of brain metastases to irinotecan-based chemotherapy. Journal of Clinical Neuroscience, 12(3), 242-245. https://doi.org/10.1016/j.jocn.2004.08.007